OpenAI acquires Orchestra Bio to help new treatments reach patients sooner
OpenAI announced it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of developing a drug. OpenAI says the team will build on Rosalind, its AI models and tools for life sciences research, to streamline those operations. The stated goal is to help new treatments reach patients sooner. These details come from the post by @OpenAI and the company’s announcement.